The remarkable diversity of clinical features that are better, the same, or worse than before? Next, the clinician should estimate whether irreversible damage is evident in patients with systemic lupus erythematosus (SLE ) demands particular vigilance on the part of the present from the disease or its treatment. Monitoring for drug toxicity is essential to minimize the long-term clinician attempting to assess and treat this complex, but fascinating, disease. Although virtually any sympmorbidity from disease. Finally, an assessment of the patient's quality of life or current functional capabilities tom one cares to think of may be due to active lupus (particularly in the central nervous system), the physiis needed because the patient's perceptions may not mirror their physician's. cian must also guard against the fallacy that every clinical problem experienced by a patient with lupus is Identification of disease and treatment of disease flares (potentially reversible problems) while minimizing organ due to the disease. In this review, we will put forward the view that in order to understand the totality of the damage (irreversible problems) and drug toxicity can be difficult in lupus for many reasons. Sometimes it is not effect of a disease like lupus upon a patient, measures are needed that distinguish disease activity (implying clear whether one can attribute symptom, sign or laboratory test to lupus. Symptoms from multiple organs can that the problems can be corrected), damage (meaning permanent change) and the patient's own perception of change simultaneously or sequentially over time. Semiquantitative measures of disease activity are being their health status.
used increasingly in clinical research and improve our ability to compare studies to one another [1] . These
Practical assessment of patients with lupus in measures are discussed in detail in subsequent sections the clinic or hospital ward of this review. They are currently being modified for use in clinical trials [2] , but their utility and practicality in A comprehensive approach in a chronic disease characclinical practice is not clear. However, they can provide terized by exacerbations and remissions is needed in all a useful guide towards understanding the spectrum of settings in which clinicians assess lupus patients.
disease the clinician must assess in the patient with lupus. Therefore, patients seen in the out-patient clinic or hospital, and those participating in a clinical drug trial, need a careful evaluation that assesses the current status What should be assessed? of the patient, but also looks to the future in order to
The protean manifestations of lupus require a thorough prevent or minimize irreversible damage from the disease search for signs and symptoms of disease. The clinical or its treatment.
review includes probing for constitutional symptoms (e.g. fatigue, fever, weight loss of >5% of body mass)
What are the goals and challenges of and screening by history and examination for mucocutaneous, musculoskeletal, cardiopulmonary, gastroassessment in lupus patients?
intestinal, lymphoreticular, neuropsychiatric and ocular At the end of the patient's visit, the clinician should manifestations. have an assessment that includes current disease activity Laboratory monitoring includes a full blood count and attempts to answer the question: is the disease and differential white cell count ( lymphopenia is a common feature in lupus patients). Since renal disease may be silent, a urinalysis looking for red cells, white urine collection should be obtained to assess the total daily protein loss. The glomerular filtration rate is most would be expected to have differing levels of disease activity (construct validity). often assessed by measuring the creatine clearance. This is not entirely accurate as creatinine is secreted actively Two main types of activity measures have been evolved. by the renal tubules. An alternative is 51Cr-labelled
The global score systems are aimed at providing a simple EDTA, the clearance of which can be assessed from the overall measure of activity. In contrast, individual plasma radioactivity at one time point following an i.v.
organ/system assessment scales seek to emphasize the dose (rather than collecting timed urine samples).
diverse nature of lupus and thus to avoid a single score Autoantibody determinations including antinuclear antion the grounds that they are too reductionist. body, anti-Ro/SSA, anti-La/SSB, anti-RNP, anti-Sm
The best known global disease activity measures are the and anticardiolipin facilitate the diagnosis of lupus or SLAM (Systemic Lupus Activity Measure) [4] , SLEDAI its subsets. Only anti-double-stranded DNA antibodies (Systemic Lupus Erythematosus Disease Activity Index) are thought to be helpful by some, but not all, investi- [5] and ECLAM ( European Community Lupus Activity gators [1] . Similarly, changes in complement componMeasure) [6 ] . Derived from a very different philosophical ents [notably C3, C4 or, if available, their breakdown standpoint, the BILAG (British Isles Lupus Assessment products (C3d or C4d)] may assist with prognosis and Group) index was developed initially in 1984 in an attempt monitoring of therapy in some patients [1] .
to move away from the global score approach. It is based Organ damage can be assessed on a yearly basis with upon the 'intention-to-treat' premise [7] . Each index has the Systemic Lupus International Collaborative Clinics/ been shown to have validity using the criteria set out in American College of Rheumatology (SLICC/ACR) the previous paragraph. damage index, which is discussed in detail in a sub-
The original SLEDAI index was developed from a sequent section. A strategy for monitoring drug toxicity meeting in Toronto in 1985, through a nominal group in lupus patients was suggested in a recent review [1] .
process, whereby a list of 24 variables was produced, Briefly, the authors suggested using the practice guidethought to be important by the participants in describing lines for monitoring drug toxicity in rheumatoid arthritis disease activity in SLE. These variables were then used to developed by the American College of Rheumatology evaluate disease activity in a cohort of patient profiles [3] as a guide for monitoring a patient with SLE.
selected from the database of the Toronto lupus clinic. Clearly, one must adapt the approach for the indi-
The variables (or descriptors of disease activity) were vidual patient.
grouped into nine organ systems. Multiple regression Assessment of quality of life or the patient's perception models were then used to derive weights for the selected of disease is also important. In the last few years, various variables in predicting disease activity. The final scale indices have been utilized to assess this important perspectadopted included 24 items using weights ranging from 1 ive. From the patient's standpoint, these instruments are to 8, with a total maximum possible score of 105. This easy to use and require little time to complete. Valuable index measures the disease activity in the 10 day period information on the functional aspect of a patient's current prior to the assessment, within which the manifestation condition is available to the clinician. The scales and must be recorded. It is a descriptive index and has been domains measured in these instruments are described in found to be reliable in naive observers [8] , between coundetail in a subsequent section.
tries [9] and in routine use [10] . It is sensitive to change over time [11] and has been used in prognosis studies [12] . The SLEDAI has been modified slightly for use in Formal assessment of disease activity in SLE particular situations, e.g. the Mexican version of SLEDAI-known as the MEXSLEDAI [13] . In an onAs Liang et al. [4] have pointed out, between the going study in the USA, known as the SELENA (Safety mid-1950s and mid-1980s some 60 attempts were made of Estrogens in Lupus Erythematosus, National to develop a disease activity index for patients with Assessment) trial, another modification of SLEDAI is SLE. None of these attempts were adequately validated being used in which several of the descriptors have been or even shown to be reliable. The situation has changed changed. For example, vertigo has been added in 'cranial radically in the last 15 yr, however, with the description nerve disorder' and for both pleurisy and pericarditis of genuinely validated clinical activity measures. Ideally, classic and severe pain is sufficient to be recorded in the such measures should include the following components:
absence of objective data such as a pleural effusion (J. Buyon, personal communication). $ Individual variables, ascertained in a generally acceptable way (case validity). The SLAM index, in contrast, is designed to allow some assessment of disease severity [4] . It was developed $ An adequate number of variables chosen in an appropriate manner (content validity). in Boston with input from members of the Lupus Council of the American College of Rheumatology. It $ Agreement with an external criterion considered to be a superior measure of disease activity standard includes 32 items divided into 11 organ systems and includes a scoring for severity as the variables are not (criterion validity). $ Positive correlation with other clinical scales or with only scored as present, but graded on a scale of 1-3 based on severity, giving a possible total score of 86. laboratory markers of disease activity and the capacity to differentiate between patient groups who Although this index includes the concept of activity and severity, some of the measures included, such as arthraltures were due to lupus or simply coincidental findings, gia and fatigue, may not represent true disease activity, and also neurological disease may be treated with specific but rather the patient's perception of disease activity.
therapy such as anticonvulsants in those with epileptic This index has been found to be reliable [13] and has attacks or anticoagulants following strokes, rather than been used as an outcome measure in therapeutic trials.
by corticosteroids and immunosuppressants. A modified version of SLAM, SLAM-R, omits scoring Although it was not designed for this purpose, the for pneumonitis and truncates several scales.
BILAG index can be converted into a global score The ECLAM index has been described following a system, thus A = 9, B = 3, C = 1, and D and E = 0, study in which 29 centres, from 14 European countries, resulting in a potential range of 0-72. In a comparative evaluated and chose 15 items from an analysis of 704 study of 75 patients with SLE, a global score derived as patients [6 ] . These items were selected at a consensus above from BILAG was shown to correlate very highly meeting of representatives from several of the participatwith the 'genuine' global score indices, SLAM, SLEDAI ing centres. It differs from the other activity indices as and ECLAM [15] . it was directly derived from a study of a large number of real patients and the analysis of a large amount of Assessment of damage in SLE data was collected in a standardized manner during the Fifty years ago, when lupus had a 5 yr survival estimated multicentre effort.
at~50% [16 ] , mortality was an important, and largely In essence, each of these global indices scores a sufficient, measure of outcome in patients with lupus. varying number of points for involvement in particular
With the substantially improved survival figures for organs or systems. By simply adding up the points patients with lupus, it has become necessary to develop scored, a global total is arrived at. These indices have a more subtle method of assessing the overall cumulative shown sensitivity to change [10] and in a number of effect of the disease. The SLICC/ACR index was pubstudies (reviewed elsewhere [2] ) have been shown to lished in 1996 after 5 yr of preparatory work [17] . The compare well with each other.
index does not seek to attribute the cause of damage to The BILAG index was derived following detailed the disease or its treatment. For example, it merely discussions among a group of rheumatologists who records the number of items of permanent change that achieved a consensus about when to treat lupus patients have affected an individual patient since the onset of with disease-modifying therapy such as high doses of the disease. The damage score can thus only remain the corticosteroids or immunosuppressives [7] . The index same or increase with time. In order for a feature to be underwent relatively minor changes, but in its current regarded as due to damage, the change must have format has shown a high degree of between-rater varipersisted for at least 6 months. It is ascertained by ability and validity [14] .
clinical assessment or simple investigations such as urinThe BILAG index now includes a total of 86 items alysis and plain radiographs, which are widely available. in eight organs or systems, each item is scored as present
Damage is distinguished in 12 organs or systems, or absent within the previous month, with many of the including ocular, neuropsychiatric, renal, pulmonary, items being identified as new, improved, the same, or cardiovascular, peripheral vascular, gastrointestinal, worse. For an item to be recorded in one of these musculoskeletal, skin, gonadal and endocrine damage, categories, the assumption is made that the problem is and the occurrence of malignancies. Weighting was not due to lupus. Thus, a lupus patient with coincident shown to improve the ability of the index to record asthma would not have shortness of breath recorded if damage, but the index has been shown to discriminate the clinician felt that it was due to the coincident disease.
between changes in disease damage in patients with both As with the global score indices, laboratory tests make active and inactive disease, and to have good interobserup relatively little of the final score, apart from the ver reliability. haematological system, and to a lesser extent the renal In a 10 yr retrospective study of 80 patients with SLE system, for obvious reasons.
using the damage index, it was shown that renal damage Each organ or system is given a score of A-E, where A at 1 yr was predictive of end-stage renal failure [18] . denotes disease thought to be sufficiently active to require Pulmonary damage at 1 yr was predictive of death by disease-modifying treatment, prednisolone <20 mg/day 10 yr of follow-up. The study also demonstrated that or immunosuppressants, B refers to problems requiring Afro-Caribbean and Asian patients had significantly only symptomatic therapy such as antimalarials or higher mean renal and total damage scores at 10 yr than non-steroidal anti-inflammatory drugs or prednisolone the Caucasian population. A high neuropsychiatric <20 mg/day, C indicates stable, mild disease, D indicates damage score was also evident in the Asian group. a previous affected but currently inactive system and E Other studies [19, 20] have confirmed the usefulness indicates that the system/organ has never been involved and validity of this index. For example, Nossent [20] previously. However, it must be emphasized that the undertook a case note review of 90 Afro-Caribbean individual scores are determined on the basis of the prespatients with lupus who had been followed for a mean ence/absence of the items referred to above.
period of 6 yr with 'periodic assessment' of the BILAG has been shown to function well for each of SLICC/ACR damage index. The mean damage score these organs or systems, with the possible exception of the 6 months after diagnosis was 0.6 and at last assessment central nervous system. There has been particular difficulty amongst physicians in deciding whether neurological fea-2.4. The damage score correlated with a weighted aver-age of SLEDAI disease activity scores and the number Both measures have been compared in a study of 150 lupus patients [31] , with significant associations between of disease exacerbations, but not with age or steroid dose.
the corresponding domains in each measure and with global disease activity measured by BILAG, although In contrast, Alarcon et al. [21] , in a cross-sectional study of Hispanic, Afro-American and Caucasian this association is not strong, suggesting that quality of life and disease activity measured by BILAG are distinct. patients (70-80 patients in each group) whose disease duration did not exceed 5 yr, did not find a statistically
In the SF-36 index, different disease activity levels were significantly associated with different quality of life significant difference in the damage score between these three groups.
scores and showed an excellent ability to record the continuum from good health to serious illness. Disease The SLICC/ACR damage index has won widespread acceptance in the lupus research 'community'. Thus, activity had a greater effect on quality of life than age, cumulative damage or disease duration. A previous Bootsma et al.'s [22] comment that the index appeared useful in SLE 'because it has the capacity to measure study had shown that in the SF-20+, limitations in physical functioning were associated with damage to the change over time; it offers the opportunity to compare treatment arms in clinical trials and reflects cumulative musculoskeletal system, measured by the SLICC/ACR damage index, and renal disease was inversely associated damage'. It should be emphasized that long-term studies are needed. In short-term studies (up to 3 yr), it is likely with fatigue, but there were no other significant associations between this health questionnaire and the damage that only 50% of patients with lupus will register any damage.
index. USA assessing the effects of a B-cell collagen LJP394, a tions) and subsequently the Short Form-36 were safety study of oestrogens given to post-menopausal developed [25, 26 ] . The Short Form 20, however, lacks women, and two trials of monoclonal anti-CD40 ligand a particular question about fatigue, which is most in the treatment of SLE. In addition, a double-blind important in many patients with lupus. Thus, a number placebo-controlled trial of the adrenal steroid hormone of studies have been reported using the so-called SF-20+ dehydroepiandrosterone (DHEA) has just been pub-(i.e. the SF-20 questionnaire plus an additional question lished [32] . It appears to have a protective effect with concerning fatigue) [27, 28] .
respect to steroid-induced osteoporosis, but was of little Although the SF-20 appears to be a valid measure of benefit in patients with severe disease. There is thus an quality of life, the instrument used most often and urgent need to agree a format for assessing the response internationally to assess health status is the SF-36. This of a patient with lupus to these exciting new forms of index may be more appropriate as it records the contherapy. Intense discussions have been going on during tinuum from healthy to severely ill very well [29, 30] . the past 2 yr among members of the SLICC and The SF-36 is almost as quick and easy to complete as OMERACT groups, and more recently the Food and the SF-20. It has 36 questions concerning eight static Drug Administration in the USA. We are hopeful that domains predominantly occurring over the previous consensus will be reached and consider it likely month, namely, physical function, role limitations: physthat agreement requires recognition of the importance ical problems, role limitations: emotional problems, of recording a disease activity measure, a damage meassocial function, mental health, general health perception, ure, a patient health perception index, and methods of vitality and pain. The SF-36 is broader than the SF-20, recording toxicity and economic costs. Only by assessing asking questions about vitality and general health (over each of these factors will we be able to determine the previous year) not found in the SF-20. Other whether new drugs provide overall benefit for a patient. domains have a broader and deeper perspective, as, for
It seems logical to us that clinical researchers around example, physical function includes specific questions the world, who are interested in lupus, should compare about lifting groceries, climbing one or several flights of the outcome of their studies in the same way. The stairs and walking different longer distances. It is scored optimal way to do this is to ensure that everyone uses in a similar way to the SF-20, with a score of 0-10-0; higher values indicating better health.
the same drug responder index.
